Armistice Capital’s Adicet Bio ACET Stock Holding History

Armistice Capital’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-31,464	Closed	-$5.25M	–	80
2019 Q4	$5.25M	Buy	+31,464	New	+$15.9M	0.3%	64

Other funds holding ACET

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ruffer LLP London, United Kingdom $2.83B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Armistice Capital's ACET Position: Q1 2020 in Review

Armistice Capital sold out of Adicet Bio (ACET) in Q1 2020, closing a stake of 31,464 shares — an estimated $5.25M sold.

Armistice Capital first reported a position in ACET in Q4 2019 and held it in 1 quarter. The position peaked at $5.25M in Q4 2019. 51 funds tracked by Wall St. Rank hold ACET as of Q1 2020.

Armistice Capital reported no remaining Adicet Bio position as of Q1 2020 after selling out during the quarter.
Armistice Capital sold 31,464 Adicet Bio shares in Q1 2020, an estimated $5.25M.
Armistice Capital first reported a position in Adicet Bio in Q4 2019 and held it in 1 quarter.
Armistice Capital's Adicet Bio position peaked at $5.25M in Q4 2019.
51 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2020.

Based on Armistice Capital's 13F filing for Q1 2020, filed 15 May 2020.